Bone marrow pathology in SCD, such as decreased mesenchymal stem cell function and disordered vasculature, has recently been described in pre-clinical models and has been shown to be responsive to red cell transfusion. A speaker will review her and others’ research in this area and its implications for peri-transplant transfusion support. Another speaker will discuss the association of HLA and red cell alloantibodies with important allogeneic transplant outcomes in SCD such as graft versus host disease, donor T cell chimerism, and even overall survival. Both speakers will speak to the implication of these findings for best practice transfusion support for SCD patients pre- and peri-transplant.
All relevant financial relationships have been mitigated.
Describe the potential of transfusion to improve allogeneic transplant and gene therapy outcomes in SCD through its effects on the bone marrow microenvironment.
Describe the association of HLA and red cell alloantibodies with allogeneic transplant outcomes in SCD.
Discuss best practice of transfusion support for SCD patients pre- and peri-transplant in the autologous and allogeneic setting.